Genemarkers has developed ex vivo tissue models that mimic key components of atopic dermatitis (AD) and psoriasis to facilitate research of topical compounds for preclinical and clinical drug development. Our scientific team has verified the expression of over 30 AD-specific and 400 psoriasis-specific gene expression biomarkers in the tissue models. Our stimulated ex vivo tissue models are ideal for performing studies investigating the efficacy of therapeutic compounds. Study endpoints may include: RNA sequencing [...]

Genemarkers’ Dr. Anna Langerveld joined BerryDunn’s Robyn Hoffmann and Regina Alexander on the Healthcare Compliance Insights Podcast. During the episode, they discuss revenue integrity and how to foster a culture of compliance in independent laboratories.   “Compliance is embedded in the culture and mission of Genemarkers. Our entire value proposition is based on quality, integrity, and compassion. Compliance is a big component of quality and integrity,” says Dr. Langerveld.   To learn how Genemarkers [...]

CPESN® USA announces the expansion of their strategic relationship with Genemarkers, LLC, a pharmacogenomic (PGx) testing laboratory in Michigan. Through this national program, CPESN pharmacies identify patients that would benefit from PGx testing, collect patient DNA samples via a buccal swab, and review the results with their patient and the healthcare provider. This personalized medicine tool determines if a medication will be safe and efficacious. PGx testing has been proven to reduce adverse drug [...]

Genemakers’ Clinical Testing Specialist, Stephanie Wheeler, was interviewed by Thermo Fisher Scientific to discuss pharmacogenomic (PGx) testing, its benefits, and how to implement a PGx testing program. Using Thermo Fisher Scientific’s state-of-the-art real-time qPCR technologies, Genemarkers offers high-quality PGx testing services rooted in clinical validity/utility. “From the beginning, we have performed our PGx testing using qPCR due to the flexibility and efficient workflow for processing the samples. The format allows us to customize the [...]

Adverse drug events (ADEs) are the 4th leading cause of death in the United States, leading to 1.3 million emergency department visits and 350,000 hospitalizations annually.1 Each year, 4.5 million ADEs occur in the US, resulting in $2.5 billion in related healthcare costs.2-4 As many as half of ADEs are considered preventable, yet they continue to pose a serious public health risk with significant financial consequences. As the need to prevent ADEs becomes more [...]

Genemarkers LLC is pleased to announce it has been recognized as one of the Top 10 Pharmacogenomic (PGx) Service Providers of 2023 by Pharma Tech Outlook.   Pharma Tech Outlook is a leading industry publication bringing together insight from senior leaders in Pharma and Life Sciences. Each year, Pharma Tech Outlook recognizes the top PGx service providers. Genemarkers is honored to accept this accolade.    As a pioneer in PGx testing, Genemarkers is a trusted [...]

What are ADEs and Polypharmacy? An adverse drug event, or ADE, occurs when a person is harmed due to a prescription medication. This can include known medication side effects or medication errors. About half of ADEs are considered preventable, yet they continue to pose a significant public health risk with substantial financial consequences. Approximately 1.3 million emergency visits1, 350,000 hospitalizations1, and $3.5 billion in excess medical costs2 occur annually in the United States from [...]

Genemarkers LLC is pleased to announce the publication of the paper, Reproducible method for assessing the effects of blue light using in vitro human skin tissues, in the International Journal of Cosmetic Science. High-intensity visible light (HEV), also known as blue light, accounts for approximately one-third of visible light. Electronic devices and artificial lighting are top emitters of blue light. Previous research has established that exposure to blue light for periods as short as 1 hour can [...]

Genemarkers is proud to announce today that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) approved Genemarkers pharmacogenomic (PGx) test panels. CLEP approval means that healthcare providers in New York can now utilize Genemarkers PGx tests in their clinical practice. “This is an important milestone for us. CLEP approval is one of the toughest accreditations to achieve, and our staff did an excellent job meeting the bar,” said Anna Langerveld, Founder [...]

Genemarkers has been providing high-quality clinical genetic testing since 2014. As a pioneer in the pharmacogenomic (PGx) testing industry, Genemarkers remains committed to creating tests that include drug-gene pairs with the highest levels of clinical validity and utility. We know healthcare providers count on us to supply reliable test data to guide their prescribing. In response to recent changes in Centers for Medicare & Medicaid Services (CMS) and other payer guidelines, and to meet the needs [...]

The National Action Plan for Adverse Drug Event Prevention An adverse drug event (ADE) is defined as harm that results from a medication intervention1. Approximately 1.3 million emergency department visits, 350,000 hospitalizations 2, and $2.5 billion in excess medical costs occur annually in the United States from ADEs2. ADEs are the 4th leading cause of death in the US. In 2014, The United States Department of Health and Human Services (USDHHS) implemented The National [...]

Genemarkers is honored to be one of 12 small businesses and nonprofits selected to receive the Pure Michigan Business Connect COVID-19 Emergency Access and Retooling Grants program for $104K to provide COVID-19 (SARS-CoV-2) testing in their CLIA-certified laboratory in downtown Kalamazoo, Michigan. Genemarkers began hearing the call from medical and public health experts across the country for more COVID-19 testing earlier this winter. As experts in high complexity testing, Genemarkers’ scientists have been actively planning [...]

Genemarkers detailed how a new gene expression panel tests the biological efficacy of CBD extracts and the cosmetic formulas containing them at the Annual Scientific Meeting & Technology Showcase. CBD is a non-psychoactive cannabinoid extracted from the hemp plant. Its effects are mediated through the CB1 and CB2 skin receptors, whose expression initiates signaling cascades relevant to both pain and inflammation. Our data demonstrate that the topical application of CBD regulates over 150 [...]